PRMT5 and lymphoma: Left untreated, engrafted mice succumbed to expanding leukemia/lymphoma with a median overall survival of 67 days (range 66–75 days, Supplemental Fig. 6D), and tumor histology was similar to that of transgenic Eμ-PRMT5/TCL1 mice with spleen and lymph node involvement and bone marrow infiltration (Supplemental Fig. 6E).